SM-164
SM-164 is a bivalent mimetic of Smac with Ki values of 0.31 nM, 1.1 nM and 0.56 nM for cIAP-1, cIAP-2 and XIAP, respectively 1.
SM-164 is developed as an anticancer agent. It plays its antitumor roles through inducing degradation of cellular inhibitor of apoptosis protein (cIAP)-1/2, antagonizing X-linked inhibitor of apoptosis protein (XIAP) and inducing TNFα-dependent apoptosis in tumor cells. SM-164 is a bivalent mimetic containing two SM-122 analogues. It binds to cIAP-1 protein containing bothBIR2 and BIR3 domains, cIAP-2 BIR3 protein and XIAP protein containing both BIR2 and BIR3 domains with Ki values of 0.31 nM, 1.1 nM and 0.56 nM, respectively. In tumor cells, treatment of SM-164 significantly reduced cIAP-1 level to undetectable levels (1 nM, 60 min), effectively antagonized cellular XIAP and enhanced TNFα secretion. In the MDA-MB-231 xenograft model, administration of SM-164 at dose of 5 mg/kg markedly decreased cIAP-1 level within 1 hour and activated caspase-8, caspase-9 and caspase-3 at 3 hour 1.
References:
1. Lu J, Bai L, Sun H, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer research, 2008, 68 (22): 9384-9393.
- 1. Xiaoxia Wang, Chenping Kang, et al. "Chlormequat Chloride Inhibits TM3 Leydig Cell Growth via Ferroptosis-Initiated Inflammation." Cells. 2024 Jun 5;13(11):979. PMID: 38891111
- 2. Peng He, Tingting Ai, et al. "Phosphorylation of caspase-8 by RSKs via organ-constrained effects controls the sensitivity to TNF-induced death." Cell Death Discov. 2024 May 24;10(1):255. PMID: 38789425
- 3. Xin Chen, Rongfeng Zhu, et al. "Mosaic composition of RIP1–RIP3 signalling hub and its role in regulating cell death." Nat Cell Biol. 2022 Mar 7. PMID: 35256774
- 4. Yi Zhong, Zhi Hong Zhang, et al. "Zinc finger protein 91 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation." Toxicol Lett. 2021 Dec 20;356:75-88. PMID: 34942311
- 5. Minho Won, Kyeong Ah Park, et al. "ANKRD13a controls early cell-death checkpoint by interacting with RIP1 independent of NF-κB." Cell Death Differ. 2021 Nov 27. PMID: 34839354
- 6. Monisha Samuel, Pamali Fonseka, et al. "Oral administration of bovine milk-derived extracellular vesicles induces senescence in the primary tumor but accelerates cancer metastasis." Nat Commun. 2021 Jun 24;12(1):3950. PMID: 34168137
- 7. Binghua Liu, Weiyan Wang, et al. "Sodium iodate induces ferroptosis in human retinal pigment epithelium ARPE-19 cells." Cell Death Dis. 2021 Mar 3;12(3):230. PMID: 33658488
- 8. Miles MA, Caruso S, et al. "Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic." Apoptosis. 2020;10.1007/s10495-020-01610-8. PMID: 32440848
- 9. Lei W, Duan R, et al. "The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice." Sci Rep. 2020;10(1):7004. PMID: 32332865
- 10. Mario G. Hollomon, LaNisha Patterson, et al. "Knockdown of Fas-Associated Protein withDeath Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death." Journal of Cancer.2019.
- 11. Heidegger S, Wintges A, et al. "RIG-I activation is critical for responsiveness to checkpoint blockade." Sci Immunol. 2019 Sep 13;4(39). pii: eaau8943. PMID: 31519811
- 12. Hendrika W. Grievink, Jules A. A. C. Heuberger, et al. "DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers." Clinical Pharmacology & Therapeutics. 22 August 2019.
- 13. Alexander F. G. Wintges. "Tumor immunosurveiliance: Innate immune activation as a mechanistic prerequisite for efficient immune checkpoint blockade in cancer immunotherapy." d-nb.info. 2018.
- 14. Saleh D, Degterev A. "Chemical Library Screens to Identify Pharmacological Modulators of Necroptosis." Methods Mol Biol. 2018;1857:19-33. PMID: 30136227
- 15. Hao Q, Tang H. "Interferon-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner." Cancer Cell Int. 2018 Jun 14;18:84. PMID: 29946223
- 16. Gavin C. Sampey, David M. Irlbeck, et al. "The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent" bioRxiv.2018.May 2.
- 17. Sarhan J, Liu BC, et al. "Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis." Cell Death Differ. 2018 May 21. PMID: 29786074
- 18. Yang Z, Wang Y, et al. "RIP3 targets pyruvate dehydrogenase complex to increase aerobic respiration in TNF-induced necroptosis." Nat Cell Biol. 2018 Feb;20(2):186-197. PMID: 29358703
- 19. Chen X, He WT, et al."Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis." Cell Res. 2016 Sep;26(9):1007-20. PMID: 27573174
- 20. Shekhar TM, Miles MA, et al."IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα."Oncotarget. 2016 Jun 7;7(23):33866-86. PMID: 27129149
| Storage | Store at -20°C |
| M.Wt | 1121.42 |
| Cas No. | 957135-43-2 |
| Formula | C62H84N14O6 |
| Solubility | ≥56.07 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| Chemical Name | (3S,6R,10aR)-6-((S)-2-(methylamino)propanamido)-N-((R)-(1-(4-(4-(4-(4-((S)-((3S,6S,10aS)-6-((S)-2-(methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamido)(phenyl)methyl)-1H-1,2,3-triazol-1-yl)butyl)phenyl)butyl)-1H-1,2,3-triazol-4-yl)( |
| SDF | Download SDF |
| Canonical SMILES | O=C([C@H]1N(C([C@@H](NC([C@H](C)NC)=O)CCCC2)=O)[C@]2([H])CC1)N[C@H](C3=CN(CCCCC4=CC=C(CCCCN5C=C([C@H](NC([C@@H]6CC[C@](CCCC[C@@H]7NC([C@@H](NC)C)=O)([H])N6C7=O)=O)C8=CC=CC=C8)N=N5)C=C4)N=N3)C9=CC=CC=C9 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Kinase experiment [1]: | |
|
Fluorescence-polarization-based binding assays for XIAP, cIAP-1 and cIAP-2 proteins |
To determine the binding affinities of SM-164 to XIAP containing both BIR2 andBIR3 domains, an FP-based competitive binding assay was established using a bivalent fluorescently tagged tracer, named Smac-1F. The Kd value of the bivalent tagged tracer to XIAP containing BIR2 and BIR3 domains was determined to be 2.3 nM. In competitive binding experiments, a tested compound was incubated with 3 nM of XIAP protein containing both BIR2 and BIR3 domain (residues 120-356) and 1 nM of in the same assay buffer. |
| Cell experiment [1]: | |
|
Cell lines |
MDA-MB-231 breast cancer cell |
|
Preparation method |
Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
12 h-48 h |
|
Applications |
12 h 1 nmol/L SM-164 treatment induces 32%, 33%, and 37% of the MDA-MB-231, SK-OV-3 and MALME-3M cells to undergo apoptosis. SM-164 also leads to cIAP-1 degradation in resistant cancer cell line and effectively antagonizes cellular XIAP. Moreover, 3 to 10 nmol/L SM-164 induces cell death with or without TNFα in all these sensitive cancer cell lines. |
| Animal experiment [1]: | |
|
Animal models |
MDA-MB-231 xenograft tumor mice model |
|
Dosage form |
A single i.v. dose of SM-164 at 5 mg/kg. |
|
Applications |
At the 3-hour time point, SM-164 induces prominent apoptosis in tumor tissues, and more than 50% of tumor cells were TUNEL positive at the 6-hour time point. SM-164 reduces the tumor volume from 147 ± 54 mm3 (day 25-start of the treatment) to 54 ± 32 mm3 (day 36-end of treatment), a 65% reduction. SM-164 treatment also shows no significant weight loss or sign of toxicity. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: 1. Lu J, Bai L, Sun H, Nikolovska-Coleska Z et al.SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15; 68 (22): 9384-93. |
|
| Targets | IAP | |||||
| IC50 | 0.56 nM/0.31 nM/1.1 nM |
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
